Last reviewed · How we verify
MEDI3250
MEDI3250 is a bispecific antibody that simultaneously engages PD-L1 on tumor cells and 4-1BB on T cells to enhance anti-tumor immune responses.
MEDI3250 is a bispecific antibody that simultaneously engages PD-L1 on tumor cells and 4-1BB on T cells to enhance anti-tumor immune responses. Used for Advanced or metastatic solid tumors (in clinical development).
At a glance
| Generic name | MEDI3250 |
|---|---|
| Sponsor | AstraZeneca |
| Drug class | Bispecific antibody; PD-L1/4-1BB bispecific |
| Target | PD-L1 and 4-1BB (CD137) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
By bridging PD-L1 expressing tumors with 4-1BB on T cells, MEDI3250 blocks the PD-L1/PD-1 inhibitory axis while providing costimulatory 4-1BB signaling. This dual mechanism aims to overcome immune checkpoint suppression and amplify T cell activation and proliferation within the tumor microenvironment.
Approved indications
- Advanced or metastatic solid tumors (in clinical development)
Common side effects
- Immune-related adverse events (irAEs)
- Fatigue
- Infusion reactions
Key clinical trials
- A Phase3 Study to Evaluate the Efficacy and Safety of MEDI3250 in Healthy Japanese Children Age 7 Years Through 18 Years (PHASE3)
- A Phase 3 Open-label Study to Evaluate the Safety of MEDI3250 in Healthy Japanese Children Age 2 Years Through 6 Years (PHASE3)
- A Study to Evaluate the Immunogenicity of Quadrivalent LAIV in Adults 18 to 49 Years of Age (PHASE2, PHASE3)
- A Study to Evaluate the Immunogenicity of Quadrivalent Live Attenuated Influenza Vaccine (LAIV) in Children (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MEDI3250 CI brief — competitive landscape report
- MEDI3250 updates RSS · CI watch RSS
- AstraZeneca portfolio CI